Epstein Barr virus-associated lymphoproliferative diseases: The virus as a therapeutic target

Experimental and Molecular Medicine

Volumn 47, Issue 1, 2015, Pages

  Tse, Eric ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA ANTIGEN; PREDNISOLONE; RITUXIMAB; THYMIDINE KINASE; VALACICLOVIR; VINCRISTINE; VIRUS ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; BURKITT LYMPHOMA; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DNA METHYLATION; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; HLA MATCHING; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOGENICITY; LARGE CELL LYMPHOMA; LYMPHOCYTE TRANSFUSION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMABLASTIC LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY EFFUSION LYMPHOMA; REVIEW; T LYMPHOCYTE; VIRUS GENOME; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BIOLOGICAL THERAPY; COMPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; PHYSIOLOGY;

HUMAN HERPESVIRUS 4;

ANTIVIRAL AGENTS; CELL- AND TISSUE-BASED THERAPY; DNA METHYLATION; EPSTEIN-BARR VIRUS INFECTIONS; GENOME, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VIRUS LATENCY;

EID: 84928016286     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.102     Document Type: Review

References (51)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-703.
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.
3. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of posttransplant lymphoproliferative disease. Nat Rev Clin Oncol 2012;9:510-519.
4. Babcock GJ, Thorley-Lawson DA. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A. 2000;97:12250-12255.
5. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999;190:567-576.
6. Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clin Adv Hematol Oncol 2014;12:358-371.
7. Kaplan LD. HIV-associated lymphoma. Best Pract Res Clin Haematol 2012;25:101-117.
8. Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant 2014;49:163-167.
9. Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:4992-5001.
10. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95:807-814.
11. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001;97:1165-1171.
12. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369.
13. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502-1505.
14. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
15. Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995;4:73-79.
16. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C. B-17 scid/scid mice. J Exp Med 1996;183:1215-1228.
17. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
18. Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998;91:2925-2934.
19. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virusinduced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
20. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925-935.
21. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012;119:2644-2656.
22. Chan TS, Hwang YY, Gill H, Au WY, Leung AY, Tse E et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant 2012;26:679-683.
23. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038-1046.
24. Emanuel DJ, Lucas KG, Mallory GB Jr, Edwards-Brown MK, Pollok KE, Conrad PD et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997;63:1691-1694.
25. Haque T, Taylor C, Wilkie GM, Murad P, Amlot PL, Beath S et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001;72:1399-1402.
26. Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:2592-2598.
27. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006;108:2942-2949.
28. Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa A et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005;5:1415-1422.
29. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-442.
30. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007;110:1123-1131.
31. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010;116:5045-5049.
32. Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH et al. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol 2014;167:402-410.
33. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997;89:1978-1986.
34. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004;200:1623-1633.
35. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002;100:4059-4066.
36. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014;32:798-808.
37. Tempera I, Lieberman PM. Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 2014;26:22-29.
38. Robertson KD, Ambinder RF. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 1997;90:4480-4484.
39. Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 1996;88:3129-3136.
40. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 2014;26:60-68.
41. Ghosh SK, Perrine SP, Williams RM, Faller DV. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012;119:1008-1017.
42. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109:2571-2578.
43. Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F et al. Viral response to chemotherapy in endemic burkitt lymphoma. Clin Cancer Res 2010;16:2055-2064.
44. Olson D, Gulley ML, Tang W, Wokocha C, Mechanic O, Hosseinipour M et al. Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi. Clin Lymphoma Myeloma Leuk 2013;13:112-118.
45. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-852.
46. Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002;21:547-554.
47. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-2900.
48. Hierro L, Díez-Dorado R, Díaz C, De la Vega A, Frauca E, Camarena C et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008;14:1185-1193.
49. Gill H, Hwang YY, Chan TS, Pang AW, Leung AY, Tse E et al. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab. J Clin Virol 2014;59:255-258.
50. Hsu JL, Glaser SL. Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000;34:27-53.
51. Kanegane H, Nomura K, Miyawaki T, Tosato G. Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit Rev Oncol Hematol 2002;44:239-249.